Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Journal of Pathology, Wiley, Vol. 237, No. 2 ( 2015-10), p. 203-214
    Abstract: Malignant pleural mesothelioma ( MPM ) is a devastating malignancy characterized by invasive growth and rapid recurrence. The identification and inhibition of molecular components leading to this migratory and invasive phenotype are thus essential. Accordingly, a genome‐wide expression array analysis was performed on MPM cell lines and a set of 139 genes was identified as differentially expressed in cells with high versus low migratory activity. Reduced expression of the novel tumour suppressor integrin α7 ( ITGA7 ) was found in highly motile cells. A significant negative correlation was observed between ITGA7 transcript levels and average displacement of cells. Forced overexpression of ITGA7 in MPM cells with low endogenous ITGA7 expression inhibited cell motility, providing direct evidence for the regulatory role of ITGA7 in MPM cell migration. MPM cells showed decreased ITGA7 expressions at both transcription and protein levels when compared to non‐malignant mesothelial cells. The majority of MPM cell cultures displayed hypermethylation of the ITGA7 promoter when compared to mesothelial cultures. A statistically significant negative correlation between ITGA7 methylation and ITGA7 expression was also observed in MPM cells. While normal human pleura samples unambiguously expressed ITGA7 , a varying level of expression was found in a panel of 200 human MPM samples. In multivariate analysis, ITGA7 expression was found to be an independent prognostic factor. Although there was no correlation between histological subtypes and ITGA7 expression, importantly, patients with high tumour cell ITGA7 expression had an increased median overall survival compared to the low‐ or no‐expression groups (463 versus 278 days). In conclusion, our data suggest that ITGA7 is an epigenetically regulated tumour suppressor gene and a prognostic factor in human MPM . Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
    Type of Medium: Online Resource
    ISSN: 0022-3417 , 1096-9896
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 1475280-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Oncotarget, Impact Journals, LLC, Vol. 6, No. 1 ( 2015-01-01), p. 394-408
    Type of Medium: Online Resource
    ISSN: 1949-2553
    URL: Issue
    Language: English
    Publisher: Impact Journals, LLC
    Publication Date: 2015
    detail.hit.zdb_id: 2560162-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 122-122
    Abstract: DNA methylation (referred to as methylation) is part of the epigenetic gene regulation complex which is relevant for the pathogenesis of different malignant diseases including non-small cell lung cancers (NSCLC). Recently, it has been reported that besides protein encoding genes also microRNA (miRNA) encoding genes may be targets for methylation in NSCLCs, however, the number of known methylated miRNA genes is still small. To investigate the role of methylation on miRNA gene silencing in NSCLCs, we performed microarray expression analyses of 856 miRNA genes in NSCLC A549 cells before and after treatment with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A. Comparing microarray data of untreated and drug treated A549 cells, we identified 33 miRNA genes whose expression was upregulated after drug treatment and which are associated with a CpG island. Methylation of these miRNA genes was determined in 11 NSCLC cell lines by methylation-sensitive high resolution melting (MS-HRM) analysis and 30 of 33 (91%) miRNA genes were found to be methylated in at least 1 NSCLC cell line. In addition, methylation of the miRNA genes miR-9-3 and miR-193a was also analysed in primary tumors and corresponding non-malignant lung tissue samples of 101 stage I-III NSCLC patients and was found to be tumor-specific. Moreover, we compared miR-9-3 and miR-193a methylation results and clinico-pathological characteristics of NSCLC patients. We found a shorter disease-free survival of miR-9-3 methylated lung squamous cell carcinoma (LSCC) patients compared to miR-9-3 unmethylated LSCC patients by multivariate analysis (HR = 3.8, 95% CI = 1.3 to 11.2, p = 0.017) and a shorter overall survival of miR-9-3 methylated LSCC patients compared to miR-9-3 unmethylated LSCC patients by univariate analysis (p = 0.013). In conclusion, our results suggest that methylation is an important mechanism for silencing certain miRNA genes in NSCLCs and that miR-9-3 methylation may serve as a prognostic parameter in LSCC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 122. doi:1538-7445.AM2012-122
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: The Journal of Pathology, Wiley
    Abstract: Wilms tumors (WTs) are histologically diverse childhood cancers with variable contributions of blastema, stroma, and epithelia. A variety of cancer genes operate in WTs, including the tripartite‐motif‐containing‐28 gene ( TRIM28 ). Case reports and small case series suggest that TRIM28 mutations are associated with epithelial morphology and WT predisposition. Here, we systematically investigated the prevalence of TRIM28 inactivation and predisposing mutations in a cohort of 126 WTs with 〉 2/3 epithelial cells, spanning 20 years of biobanking in the German SIOP93‐01/GPOH and SIOP2001/GPOH studies. Overall, 44.4% (56/126) cases exhibited loss of TRIM28 by immunohistochemical staining. Of these, 48 could be further analyzed molecularly, revealing TRIM28 sequence variants in each case – either homozygous (~2/3) or heterozygous with epigenetic silencing of the second allele (~1/3). The majority (80%) of the mutations resulted in premature stops and frameshifts. In addition, we detected missense mutations and small deletions predicted to destabilize the protein through interference with folding of key structural elements such as the zinc‐binding clusters of the RING, B‐box‐2, and PHD domains or the central coiled‐coil region. TRIM28‐ mutant tumors otherwise lacked WT‐typical IGF2 alterations or driver events, except for rare TP53 progression events that occurred with expected frequency. Expression profiling identified TRIM28‐ mutant tumors as a homogeneous subset of epithelial WTs that mostly present with stage I disease. There was a high prevalence of perilobar nephrogenic rests, putative precursor lesions, that carried the same biallelic TRIM28 alterations in 7/7 cases tested. Importantly, 46% of the TRIM28 mutations were present in blood cells or normal kidney tissue, suggesting germline events or somatic mosaicism, partly supported by family history. Given the high prevalence of predisposing variants in TRIM28‐ driven WT, we suggest that immunohistochemical testing of TRIM28 be integrated into diagnostic practice as the management of WT in predisposed children differs from that with sporadic tumors. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
    Type of Medium: Online Resource
    ISSN: 0022-3417 , 1096-9896
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 1475280-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: The Journal of Pathology, Wiley, Vol. 245, No. 4 ( 2018-08), p. 387-398
    Abstract: Deregulated DNA methylation leading to transcriptional inactivation of certain genes occurs frequently in non‐small‐cell lung cancers (NSCLCs). As well as protein‐coding genes, microRNA (miRNA)‐coding genes may be targets for methylation in NSCLCs; however, the number of known methylated miRNA genes is still small. Thus, we investigated methylation of miRNA genes in primary tumour (TU) samples and corresponding non‐malignant lung tissue (NL) samples of 50 NSCLC patients by using methylated DNA immunoprecipitation followed by custom‐designed tiling microarray analyses (MeDIP‐chip), and 252 differentially methylated probes between TU samples and NL samples were identified. These probes were annotated, which resulted in the identification of 34 miRNA genes with increased methylation in TU samples. Some of these miRNA genes were already known to be methylated in NSCLCs (e.g. those encoding miR‐9‐3 and miR‐124), but methylation of the vast majority of them was previously unknown. We selected six miRNA genes (those encoding miR‐10b, miR‐1179, miR‐137, miR‐572, miR‐3150b, and miR‐129‐2) for gene‐specific methylation analyses in TU samples and corresponding NL samples of 104 NSCLC patients, and observed a statistically significant increase in methylation of these genes in TU samples ( p   〈  0.0001). In silico target prediction of the six miRNAs identified several oncogenic/cell proliferation‐promoting factors (e.g. CCNE1 as an miR‐1179 target). To investigate whether miR‐1179 indeed targets CCNE1 , we transfected miR‐1179 gene mimics into CCNE1 ‐expressing NSCLC cells, and observed downregulated CCNE1 mRNA expression in these cells as compared with control cells. Similar effects on cyclin E1 expression were seen in western blot analyses. In addition, we found a statistically significant reduction in the growth of NSCLC cells transfected with miR‐1179 mimics as compared with control cells. In conclusion, we identified many methylated miRNA genes in NSCLC patients, and found that the miR‐1179 gene is a potential tumour cell growth suppressor in NSCLCs. Overall, our findings emphasize the impact of miRNA gene methylation on the pathogenesis of NSCLCs. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
    Type of Medium: Online Resource
    ISSN: 0022-3417 , 1096-9896
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 1475280-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Carcinogenesis, Oxford University Press (OUP), Vol. 34, No. 3 ( 2013-3), p. 513-521
    Type of Medium: Online Resource
    ISSN: 1460-2180 , 0143-3334
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 1474206-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 18, No. 6 ( 2012-03-15), p. 1619-1629
    Abstract: Purpose: The major aim of this study was to investigate the role of DNA methylation (referred to as methylation) on miRNA silencing in non–small cell lung cancers (NSCLC). Experimental Design: We conducted microarray expression analyses of 856 miRNAs in NSCLC A549 cells before and after treatment with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A. miRNA methylation was determined in 11 NSCLC cell lines and in primary tumors and corresponding nonmalignant lung tissue samples of 101 patients with stage I–III NSCLC. Results: By comparing microarray data of untreated and drug-treated A549 cells, we identified 33 miRNAs whose expression was upregulated after drug treatment and which are associated with a CpG island. Thirty (91%) of these miRNAs were found to be methylated in at least 1 of 11 NSCLC cell lines analyzed. Moreover, miR-9-3 and miR-193a were found to be tumor specifically methylated in patients with NSCLC. We observed a shorter disease-free survival of patients with miR-9-3 methylated lung squamous cell carcinoma (LSCC) than patients with miR-9-3 unmethylated LSCC by multivariate analysis [HR = 3.8; 95% confidence interval (CI), 1.3–11.2, P = 0.017] and a shorter overall survival of patients with miR-9-3 methylated LSCC than patients with miR-9-3 unmethylated LSCC by univariate analysis (P = 0.013). Conclusions: Overall, our results suggest that methylation is an important mechanism for inactivation of certain miRNAs in NSCLCs and that miR-9-3 methylation may serve as a prognostic parameter in patients with LSCC. Clin Cancer Res; 18(6); 1619–29. ©2012 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 14_Supplement ( 2016-07-15), p. 2766-2766
    Abstract: Deregulated DNA methylation (referred to as methylation) leading to transcriptional inactivation of certain genes occurs frequently in non-small cell lung cancers (NSCLC). Besides protein encoding genes also microRNA (miRNA) encoding genes were found to be targets for methylation in NSCLCs, however, the number of known methylated miRNA genes is still small. Thus, we investigated genome-wide methylation of miRNA genes in primary tumors (TU) and corresponding non-malignant lung tissue samples (NL) of 50 NSCLC patients using methylated DNA immunoprecipitation followed by custom designed tiling microarray analyses (MeDIP-chip). Differentially methylated miRNA genes between TU and NL samples were identified using paired t-statistics with permutation adjusted p-values for step down multiple testing. Using this approach, 201 differentially methylated probes between TU and NL samples were found. These probes were annotated resulting in the identification of 39 tumor-specifically methylated miRNA genes. 79% of them are associated with a 5′ CpG island. While some of these miRNA genes were already known to be methylated in NSCLCs (e.g. miR-9-3, miR-124) methylation of the vast majority of them was unknown so far. We selected 6 miRNA genes (miR-10b, miR-1179, miR-137, miR-572, miR-3150b and miR-129-2) for gene-specific methylation analyses in TU and corresponding NL samples of 108 NSCLC patients and observed statistically significant tumor-specific methylation of these miRNA genes which confirmed our MeDIP-chip data (p & lt;0.0001, respectively). Using miRWalk2.0 software, we searched for predicted targets of the 6 miRNAs and identified several oncogenic/cell proliferation promoting factors. Examples of them are TFAP2C and HOXA1 (predicted miR-10b targets), HMGB3, CCNE1 and FGF11 (predicted miR-1179 targets), HOXD11 and ONECUT1 (predicted miR-572 targets). By analysing RNA-seq data of & gt; 1.000 NSCLC patients from The Cancer Genome Atlas database, we found that many of the predicted miRNA targets are upregulated in TU samples (e.g. CCNE1, HMGB3, HOXD11, TFAP2A, ZIC2). Based on these findings, we investigated if miR-1179 indeed targets CCNE1 in vitro. Thus, we transfected miR-1179 mimics into CCNE1 expressing NSCLC cell lines (HTB182 and NCI-H1650). Using RT-PCR, we found downregulated CCNE1 expression in cells transfected with miR-1179 mimics compared to cells transfected with controls. In addition, we observed downregulated CCNE1 expression in cells transfected with miR-1179 mimics compared to cells transfected with controls by Western blot analyses. Additional functional analyses of miR-1179 targets as well as of other miRNA targets are ongoing. In conclusion, we identified a large number of tumor-specifically methylated miRNA genes in NSCLC patients and found that some of these miRNAs target certain oncogenes in NSCLC cells. Overall, our findings emphasize the impact of miRNA gene methylation on the pathogenesis of NSCLCs. Citation Format: Gerwin Heller, Corinna Altenberger, Thais Topakian, Barbara Ziegler, György Lang, Adelheid End-Pfützenreuter, Irene Steiner, Sonja Zehetmayer, Balazs Döme, Walter Klepetko, Martin Posch, Christoph C. Zielinski, Sabine Zöchbauer-Müller. Genome-wide miRNA methylation analyses in non-small cell lung cancer patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2766.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 397-397
    Abstract: Epigenetic abnormalities, especially DNA methylation, are involved in the pathogenesis of non-small cell lung cancers (NSCLC). By using a genome-wide approach, we recently identified ∼ 500 tumor-specifically methylated genes in a large number of NSCLC patients and from most of them tumor-specific methylation in NSCLCs was unknown so far. One of these genes is the Sperm Associated Antigen 6 (SPAG6) gene. By analysing publically available IlluminaHiSeq RNA-seq data from “The Cancer Genome Atlas” database, we observed that SPAG6 mRNA expression is frequently lost in tumor samples compared to corresponding non-malignant lung tissue samples of NSCLC patients (http://cancergenome.nih.gov/). To further investigate the mechanism of SPAG6 downregulation, we studied SPAG6 expression in 5 NSCLC cell lines. We observed loss of SPAG6 expression in all of these cell lines compared to normal human bronchial epithelial cells (NHBECs). Subsequently, we treated cells of NSCLC cell lines which do not express SPAG6 with the epigenetically active drugs 5-aza-2´-deoxycytidine and Trichostatin A and observed SPAG6 reexpression. These results suggest that transcriptional regulation of SPAG6 is epigenetically regulated. Bisulfite genomic sequencing of parts of the 5´ region of SPAG6 revealed that the vast majority of CpG sites indeed are methylated in cells of NSCLC cell lines which do not express SPAG6 while no methylation was found in NHBECs. Moroever, we analysed SPAG6 methylation in tumor and corresponding non-malignant tissue samples of 147 stage I-III NSCLC patients using methylation-sensitive high-resolution melting (MS-HRM) assays. Differences in SPAG6 methylation between tumor and corresponding non-malignant lung tissue samples were statistically significant (p & lt; 0.0001) demonstrating that SPAG6 is tumor-specifically methylated. Furthermore, ROC curve analyses of methylation results revealed that methylation of SPAG6 is able to distinguish tumor samples from corresponding non-malignant lung tissue samples of NSCLC patients. We additionally investigated SPAG6 protein expression in tumor and corresponding non-malignant tissue samples of 35 NSCLC patients by immunohistochemistry. In the vast majority of tumor samples which were found to be SPAG6 methylated, SPAG6 protein expression was lost in tumor cells while SPAG6 protein expression was observed in bronchial and bronchiolar epithelial cells of non-malignant lung tissue samples. Comparison of SPAG6 methylation results with clinico-pathological data of NSCLC patients suggests a potential negative prognostic relevance of SPAG6 methylation for NSCLC patients. Currently, we determine the biological function of SPAG6 in NSCLC cell lines. Overall, our results demonstrate that DNA methylation is the major mechanism for frequent loss of SPAG6 expression in NSCLCs. Citation Format: Corinna Altenberger, Gerwin Heller, Bianca Schmid, Barbara Ziegler, Leonhard Müllauer, György Lang, Adelheid End-Pfützenreuter, Balazs Döme, Britt-Madeleine Arns, Kwun M. Fong, Casey M. Wright, Ian A. Yang, Walter Klepetko, Christoph C. Zielinski, Sabine Zöchbauer-Müller. Transcriptional regulation of SPAG6 by DNA methylation in NSCLCs. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 397. doi:10.1158/1538-7445.AM2014-397
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 14_Supplement ( 2016-07-15), p. 2772-2772
    Abstract: DNA methylation is one of the major epigenetic mechanisms regulating transcriptional activity and is involved in the pathogenesis of non-small cell lung cancers (NSCLC). In a recent study we identified a large number of tumor-specifically methylated genes in NSCLCs (Heller et al., Carcinogenesis 2013). For further detailed analyses we selected the genes SPAG6 (Sperm Associated Antigen 6) and L1TD1 (LINE-1 Type Transposase Domain Containing 1). By analysing publically available IlluminaHiSeq RNA-seq data we observed frequent downregulation of SPAG6 and L1TD1 mRNA expression in primary tumor (TU) samples compared to corresponding non-malignant lung tissue (NL) samples of NSCLC patients. In addition, we investigated SPAG6 and L1TD1 mRNA expression in 5 NSCLC cell lines and found SPAG6 as well as L1TD1 mRNA expression frequently downregulated in all of these cell lines compared to normal human bronchial epithelial cells (NHBECs). Subsequently, we treated cells of NSCLC cell lines which did not express SPAG6 or L1TD1 with the epigenetically active drugs 5-aza-2′-deoxycytidine and Trichostatin A and observed re-expression of both genes suggesting that transcriptional regulation of SPAG6 and L1TD1 is mediated by DNA methylation in NSCLCs. Bisulfite genomic sequencing of parts of the 5′ region of SPAG6 and L1TD1 revealed that the vast majority of CpG sites indeed are methylated in NSCLC cells in contrast to NHBECs. Moreover, we analysed SPAG6 and L1TD1 methylation in TU and NL samples of 147 stage I-III NSCLC patients using the gene-specific approach methylation-sensitive high resolution melt analysis (MS-HRM). Differences in SPAG6 as well as in L1TD1 methylation between TU and NL samples were statistically significant for both genes and confirmed that SPAG6 and L1TD1 are tumor-specifically methylated in NSCLCs. Additionally, we investigated SPAG6 and L1TD1 protein expression in TU and NL samples of 35 NSCLC patients by immunohistochemistry. In the vast majority of SPAG6 or L1TD1 methylated TU samples, protein expression of these genes was downregulated in tumor cells. Moreover, we performed cell proliferation, cell viability and colony formation assays in vitro and observed that ectopic expression of L1TD1 but not of SPAG6 reduced tumor cell proliferation, viability and the ability of NSCLC cells to form colonies. To further investigate the role of L1TD1 in the pathogenesis of NSCLCs, in vivo studies are being carried out. Overall, our results demonstrate that DNA methylation is the major mechanism for frequent downregulation of SPAG6 and L1TD1 expression in NSCLCs. Citation Format: Corinna Altenberger, Gerwin Heller, Barbara Ziegler, Erwin Tomasich, Maximilian Marhold, Leonhard Müllauer, György Lang, Adelheid End-Pfützenreuter, Balazs Döme, Britt-Madeleine Arns, Walter Klepetko, Christoph C. Zielinski, Sabine Zöchbauer-Müller. SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2772.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages